Inhibrx Biosciences, Inc. INBX Business Segments — Research And Development Expense, Contract Manufacturing
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept inhibrx:ResearchAndDevelopmentExpenseContractManufacturing.
The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s business segments — research and development expense, contract manufacturing.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s business segments — research and development expense, contract manufacturing?
- Inhibrx Biosciences, Inc. (INBX) reported business segments — research and development expense, contract manufacturing of $2.04M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s business segments — research and development expense, contract manufacturing changed year-over-year?
- Inhibrx Biosciences, Inc.'s business segments — research and development expense, contract manufacturing decreased by 76.1% year-over-year, from $8.55M to $2.04M.
- What does business segments — research and development expense, contract manufacturing mean?
- This metric tracks costs associated with outsourcing the production of drug candidates to third-party manufacturing organizations. It represents the financial commitment to scaling up manufacturing processes for clinical supply. Changes in this metric often correlate with the transition from early-stage development to larger clinical trials.